Similar articles

• Organizational Update: NINDS Stroke Research Strategies for Large Vessel Occlusion and Neuroprotection.

  Wright CB, Bosetti F, Janis LS, Koenig JI, Moy CS. Wright CB, et al. Stroke. 2021 Jan;52(1):e1-e2. doi: 10.1161/STROKEAHA.120.029977. Epub 2020 Dec 28. Stroke. 2021. PMID: 33370178 No abstract available.
• Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.

  Rao NM, Levine SR, Gornbein JA, Saver JL. Rao NM, et al. Stroke. 2014 Sep;45(9):2728-33. doi: 10.1161/STROKEAHA.114.005135. Epub 2014 Aug 5. Stroke. 2014. PMID: 25096731 Free PMC article.
• Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.

  Khatri P, Kleindorfer DO, Yeatts SD, Saver JL, Levine SR, Lyden PD, Moomaw CJ, Palesch YY, Jauch EC, Broderick JP. Khatri P, et al. Stroke. 2010 Nov;41(11):2581-6. doi: 10.1161/STROKEAHA.110.593632. Epub 2010 Sep 2. Stroke. 2010. PMID: 20814000 Free PMC article.
• Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.

  Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force:; Levine SR, Khatri P, Broderick JP, Grotta JC, Kasner SE, Kim D, Meyer BC, Panagos P, Romano J, Scott P; NINDS rt-PA Stroke Trial Investigators. Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force:, et al. Stroke. 2013 Sep;44(9):2500-5. doi: 10.1161/STROKEAHA.113.000878. Epub 2013 Jul 11. Stroke. 2013. PMID: 23847249 Free PMC article. Review.
• Challenges in acute ischemic stroke clinical trials.

  Furlan AJ. Furlan AJ. Curr Cardiol Rep. 2012 Dec;14(6):761-6. doi: 10.1007/s11886-012-0311-9. Curr Cardiol Rep. 2012. PMID: 22922833 Review.